^
    1d
    HORIZON 2: A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=11, Active, not recruiting, Hoffmann-La Roche | Phase classification: P3 --> P1/2 | Trial completion date: Mar 2033 --> Aug 2026 | Trial primary completion date: Jun 2028 --> Aug 2026
    Phase classification • Trial completion date • Trial primary completion date
    |
    ALK fusion
    |
    cisplatin • carboplatin • Alecensa (alectinib) • pemetrexed
    1d
    POD1UM-304: Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=583, Completed, Incyte Corporation | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Zynyz (retifanlimab-dlwr)
    1d
    ALTAIR: A Platform Study in Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=56, Recruiting, AstraZeneca | N=43 --> 56
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • Cyramza (ramucirumab) • pemetrexed • rilvegostomig (AZD2936)
    2d
    Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma (clinicaltrials.gov)
    P2, N=37, Not yet recruiting, Fudan University
    New P2 trial
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • pemetrexed • iparomlimab (QL1604)
    3d
    SAFFRON: Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (clinicaltrials.gov)
    P3, N=345, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2025 --> Jun 2026
    Enrollment closed • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • MET overexpression
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Orpathys (savolitinib)
    3d
    A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer (clinicaltrials.gov)
    P3, N=398, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • paclitaxel • pemetrexed • topotecan • SHR-A2102
    3d
    REZILIENT4: A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection (clinicaltrials.gov)
    P3, N=360, Recruiting, Taiho Oncology, Inc. | N=141 --> 360
    Enrollment change • Trial initiation date
    |
    EGFR L861Q • EGFR G719X • EGFR S768I
    |
    cisplatin • carboplatin • pemetrexed • zipalertinib (CLN-081)
    4d
    An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) (clinicaltrials.gov)
    P3, N=49, Active, not recruiting, Hoffmann-La Roche | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • paclitaxel • Xtandi (enzalutamide) • pemetrexed
    4d
    Taxanes Versus Pemetrexed After Osimertinib Resistance in EGFR-Mutated NSCLC: A Retrospective Cohort with Two-Model In Vitro Validation. (PubMed, Cancer Manag Res)
    Taxane‑based chemotherapy was associated with more favorable outcomes than pemetrexed in dramatic progression after osimertinib resistance, with higher non‑hematologic toxicity. These findings, supported by exploratory in vitro sensitivity, warrant prospective validation.
    Preclinical • Retrospective data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • pemetrexed
    5d
    Trial assessing fianlimab plus cemiplimab plus chemotherapy or cemiplimab plus chemotherapy in patients with pleural mesothelioma (2024-519208-29-00)
    P1/2, N=126, Recruiting, Intergroupe Francophone De Cancerologie Thoracique | Not yet recruiting --> Recruiting
    Enrollment open
    |
    pemetrexed • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    6d
    A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2/3, N=854, Recruiting, AbbVie | Trial completion date: Nov 2036 --> Dec 2031 | Trial primary completion date: Nov 2036 --> Dec 2031
    Trial completion date • Trial primary completion date • Adverse events
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • telisotuzumab adizutecan (ABBV-400)
    6d
    IMMUNOLIFE2: Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=162, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • MaaT033 • Navelbine oral (vinorelbine tartrate oral)